Oxymetazoline (Drixine)
Oxymetazoline
Bayer (Pty) Ltd û Isando
Every registration of this product has been cancelled.
Registration
- Applicant
- Bayer (Pty) Ltd û Isando
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Drixine 0,025% EACH 1 ML CONTAINS OXYMETAZOLINE HYDROCHLORIDE 0,25 mg | 0,025% | E0224E/16.1/224 | Cancelled | Not determined | None |
| Drixine 0,05 % EACH ml CONTAINS OXYMETAZOLINE HYDROCHLORIDE A 0,50 mg | 0,05 % | H1376 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S2: Oxymetazoline
- except when intended for nasal use
Consolidated Schedules 06 July 2026, line 2476
S1: Oxymetazoline
- when intended for nasal use.
Consolidated Schedules 06 July 2026, line 952
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
Drag to rotate. Structure from PubChem CID 4636.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.